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Abstract
During embryogenesis, the formation of primary vascular networks occurs via the processes
of vasculogenesis and angiogenesis. In uveal melanoma, vasculogenic mimicry describes
the ‘embryonic-like’ ability of aggressive, but not nonaggressive, tumor cells to form networks
surrounding spheroids of tumor cells in three-dimensional culture; these recapitulate the
patterned networks seen in patients’ aggressive tumors and correlates with poor prognosis.
The molecular profile of these aggressive tumor cells suggests that they have a deregulated
genotype, capable of expressing vascular phenotypes. Similarly, the embryonic-like
phenotype expressed by the aggressive human breast cancer cells is associated with their
ability to express a variety of vascular markers. These studies may offer new insights for
consideration in breast cancer diagnosis and therapeutic intervention strategies.
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HUVEC = human umbilical vein endothelial cell; TIE = tyrosine kinase with immunoglobulin and epidermal growth factor homology domains; VEGF
= vascular endothelial growth factor.
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Introduction
Vasculogenic mimicry in aggressive human melanoma
tumor cells will be reviewed, and new evidence regarding
the possibility of its existence in human breast cancer cells
is presented and discussed.
Molecular vasculogenic mimicry by aggressive
tumor cells
It is widely assumed that tumors require a blood supply to
survive, grow, and metastasize [1]. However, this concept
has been inextricably linked to angiogenesis, involving the
process of signaling for new blood vessel growth into a
growing tumor mass [2–5]. Recently, our laboratory and
collaborators have challenged this dogma [6,7] with data
generated from uveal and cutaneous melanoma models.
These data demonstrated that the aggressive human
melanoma tumors, but not nonaggressive tumors, consist
of matrix-rich networks surrounding spheroids of tumor
cells, in the absence of tumor necrosis and classic angio-
genesis, thus questioning the requirement of these cells
for a blood supply. These studies utilized a multidiscipli-
nary approach of investigating the pathologic indices in
patient tumors that are correlated with the data derived
from tumor cell lines in three-dimensional in vitro cultures,Breast Cancer Research    Vol 2 No 6 Hendrix et al
invasion assays, and microarray analysis of differential
gene expression in aggressive versus nonaggressive
tumor cells. Most noteworthy was the revelation that the
presence of matrix-rich networks surrounding spheroids of
tumor cells in primary and metastatic melanoma tumors
from patients correlated with the aggressiveness of these
tumors in vivo and with poor clinical outcome [8].
The cell lines derived from the aggressive and nonaggres-
sive patient tumors were further analyzed for differences in
their biologic functions in three-dimensional cultures.
These assays demonstrated the remarkable recapitulation
seen in situ of hollow and closed matrix-rich networks sur-
rounding spheroids of tumor cells, but only in the aggres-
sive tumor cell cultures. In addition, the melanoma cells
that are capable of generating these networks expressed
inappropriate vascular and other molecular markers that
represent a combination of phenotypes. These included
endothelium (tyrosine kinase with immunoglobulin and epi-
dermal growth factor homology domains [TIE]1, an
endothelial receptor kinase, plus 12 other endothelial
associated genes [6]), epithelium (keratin-8 intermediate
filaments), and a mesenchymal phenotype (vimentin inter-
mediate filaments), collectively suggesting a genetic rever-
sion to a pluripotent embryonic-like phenotype.
The unique ability of aggressive human melanoma tumor
cells to generate patterned networks, similar to the pat-
terned networks seen during embryonic vasculogenesis,
and concomitantly to express vascular markers associated
with endothelial cells, their precursors and other vascular
cells has been termed ‘vasculogenic mimicry’. However,
the physiologic significance of these networks and molec-
ular vasculogenic mimicry is unknown, and must be rigor-
ously tested in experimental animal models.
What do we know about the ability of nonendothelial cells
to function in a vascular-related capacity? There is strong
evidence suggesting that human cytotrophoblasts adopt
an endothelial cell phenotype as they actively participate in
the dynamics of establishing the placenta and primordial
microcirculation, which has been designated ‘trophoblast
pseudo-vasculogenesis’ [9–11]. With respect to tumor
vascularization, the possibility of the formation or lining of
a microcirculation by tumor cells has been suggested by
several studies, on the basis of morphologic analyses and
numerous pathology reports [12–25]. In a recent review
by Tímár and Tóth [26], the diagnostic and clinical signifi-
cance with regard to human melanoma and breast cancer
tumor cell-lined sinuses and vascular channels was pre-
sented. However, there were no experimental data to
support their functional significance. Additional studies by
Hashizume et al [27] suggested that, in certain mouse
mammary carcinoma and RIP-Tag2 models, openings
between defective endothelial cells account for tumor
vessel leakiness, leading to the lining of extravascular
blood lakes by tumor cells. However, some pathologists
have argued that tumor cells lining channels and sinuses
that contain red blood cells in a rouleau formation repre-
sents a different phenomenon from vessel leakage
[26,28], which requires further examination in appropriate
animal models for melanoma.
Over the past few years, there have been confounding
reports from distinguished scientists that dispute the rele-
vance of vascular density and clinical outcome in
melanomas [29,30], nonsmall-cell lung carcinoma [31],
oral cancers [32], esophageal cancers [33], aggressive
prostate cancers [34], and breast cancer [35]. Further his-
tomorphologic evidence that some tumors may be vascu-
larized without neo-angiogenesis, and possibly by
pre-existent organ vasculature, has been reported in non-
small-cell lung carcinomas [36]. Of special interest is the
recent report [37••] supporting a nonangiogenic as well as
an angiogenic pathway in breast cancer metastasis, which
may further complicate treatment strategies. In addition,
there are emerging data pointing to the expression of vas-
cular markers, such as the thrombin receptor in breast
cancer cells and tissue [38•], TIEs and angiopoietins in
tumor cells of Kaposi’s sarcoma [39], and vascular
endothelial growth factor (VEGF) in melanoma cells and
tissues [40].
Collectively, these data prompted us to conduct a prelimi-
nary molecular analysis of these vascular markers specifi-
cally expressed by aggressive versus nonaggressive
breast cancer cells, in order to determine whether a
pattern associated with the aggressive tumor cell pheno-
type might emerge. These data could provide additional
markers for further diagnostic testing and therapeutic
intervention strategies that might augment current anti-
angiogenesis therapies.
Expression of vascular markers by breast
cancer cells
Observational pathology reports and experimental data
suggest that keratin (a epithelial marker) and vimentin (a
mesenchymal marker) intermediate filament coexpression
in both melanoma and breast cancer confers a more
aggressive ‘interconverted’ phenotype, which is sugges-
tive of a genetic reversion to an embryonic-like cell type
[41,42]. This association between the interconverted phe-
notype expressed by both the aggressive melanoma and
breast cancer cells prompted a preliminary molecular
analysis of vascular-associated markers (expressed by
aggressive melanoma cells) that might be similarly
expressed by aggressive breast cancer cells.
Using the nonaggressive MCF-7 and aggressive
MDA-MB-231 breast cancer cell lines, molecular analysis
of specific vascular markers was performed using ribonu-
clease protection assay, differential display, and Northernhttp://breast-cancer-research.com/content/2/6/417
blot analyses (Fig. 1). The human umbilical vein endothelial
cells (HUVECs) were used as a positive control for all of
the vascular markers tested by ribonuclease protection
assay. Of the vascular molecules identified, the MCF-7
cells expressed only modest amounts of VEGF, whereas
MDA-MB-231 cells expressed higher levels. The highly
aggressive MDA-MB-231 cells expressed thrombin recep-
tor, TIE2, CD31, and VEGF; the expression patterns of
these markers most closely resembled those in the
HUVEC cells, with the exception of endoglin. Previously
performed differential display analysis [43] revealed strong
expression by MDA-MB-231 of an unknown gene, bc-48,
which has homology in the 3¢ region with endothelin-B
receptor, another endothelial associated marker. This
expression was confirmed by Northern blot analysis,
showing an intense band in MDA-MB-231 cells and no
expression in MCF-7 cells. These data are further summa-
rized in Table 1.
The extent of vascular marker expression by the highly
aggressive MDA-MB-231 cells, including thrombin recep-
tor, TIE2, CD31, VEGF, and bc-48, has been shown to be
associated with endothelial cells, as well as a few other
cell types [44–49]. Of special significance is the expres-
sion by MDA-MB-231 cells of thrombin receptor, a
member of the protease-activated receptor family. A previ-
ous report [44] showed that thrombin increases the inva-
sive activity of MDA-MB-231 cells by a thrombin
receptor-dependent mechanism, which may help to eluci-
date some of the molecular mechanisms that underlie the
invasive and metastatic ability of these highly aggressive
tumor cells. When thrombin receptor expression is experi-
mentally downregulated in highly metastatic human breast
cancer cells, their invasive ability is significantly diminished
[38•]. Interestingly, that study also highlighted the impor-
tance of thrombin receptor expression in invading cytotro-
phoblasts during placental implantation of the human
embryo [38•]. Indeed, others have shown that one of the
mechanisms of thrombin-induced angiogenesis is the
potentiation of VEGF activity on endothelial cells via the
upregulation of VEGF receptors [47], which may help to
explain the simultaneous increase in both VEGF and
thrombin receptor by MDA-MB-231 cells demonstrated in
this molecular survey.
VEGF is a critical factor in vasculogenesis and angiogene-
sis, and has been shown [40] to be expressed by
melanoma cells in a majority of metastases. TIE2, VEGF,
and CD31, collectively, have also been demonstrated in
other carcinoma cells, such as human nonsmall-cell lung
carcinomas, and are considered important angiogenic
factors [48]. The upregulation of bc-48 (by MDA-MB-231
cells), a putative endothelin-B receptor, has heretofore
been associated with vascular tube formation by endothe-
lial cells [49], and lends further support to the concept
that highly aggressive breast cancer cells are capable of
expressing vascular markers previously thought to be
associated only with endothelial cells, their precursors,
and other vascular cells. Taken together, this preliminary
molecular screen suggests for the first time that aggres-
sive breast cancer cells express a diverse subset of vascu-
lar markers, whose clinical and pathophysiological
significance requires further examination.
Significance of putative vasculogenic mimicry
in cancer
During embryogenesis, the formation of primary vascular
networks occurs via the processes of vasculogenesis and
angiogenesis. During tumorigenesis, it is tempting to
speculate that both of these processes are recapitulated
Figure 1
(A) Ribonuclease protection assay analysis, (B) differential display
analysis, and (C) Northern blot analysis of vascular markers expressed
by human breast cancer cell lines, including the following: thrombin
receptor, endothelin B receptor (methods described by Kirschmann et
al [43]), TIE2, CD31, endoglin and VEGF. Equal loading was assessed
by ribosomal protein L32 (L32) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression (A), genes not differentially
expressed (B), and b-actin (C). These data are summarized in Table 1.to provide the requisite nutritional supply to growing
tumors. Certainly, this has been proven and accepted for
angiogenesis, and there is a growing body of circumstan-
tial in vitro and molecular evidence to suggest that vascu-
logenesis may play a putative role as well. There is
additional  in vivo evidence in patients’ tumors that sup-
ports nonangiogenic pathways with possible cooption of
the existing vasculature in both nonsmall-cell lung carci-
noma and breast cancer metastasis [36,37••].
In uveal melanoma, the evolving concept of vasculogenic
mimicry describes the ‘embryonic-like’ ability of aggres-
sive, but not nonaggressive tumor cells to form channels
within matrix-rich networks surrounding spheroids of tumor
cells in three-dimensional culture, which recapitulates the
patterned networks seen in patients’ aggressive tumors
and correlates with poor prognosis. The molecular profile
of these aggressive tumor cells suggests that they have a
deregulated genotype that is capable of expressing multi-
ple molecular phenotypes simultaneously, particularly vas-
cular markers associated primarily with endothelial cells
and their precursors. The deregulated genotype also sug-
gests that the aggressive melanoma tumor cells have
essentially reverted to a pluripotent embryonic-like cell that
is capable of transdifferentiation.
Similarly, the interconverted, embryonic-like phenotype
expressed by the aggressive, but not by the nonaggressive,
human breast cancer cells is associated with their ability to
express a variety of vascular markers, at the molecular level.
However, further evidence regarding the biologic signifi-
cance of these markers in both breast cancer and
melanoma is required before specific conclusions can be
drawn. Interestingly, Drosophila researchers have recently
referred to tumor vasculogenic mimicry channels in aggres-
sive, fast-growing tumors containing mutations in the lats
tumor suppressor gene [50], which they speculate may be
important for perfusion. The Drosophila model does not
have blood flow or endothelial cells; however, these tumors
may hold quintessential clues regarding a potential hard-
wired genetic program that has been evolutionarily con-
served, which needs to be further investigated to elucidate
alternative, nonangiogenic pathways for tumor perfusion.
Obviously, there are more questions than answers at this
time regarding the putative functional significance of vas-
cular marker expression by aggressive melanoma and
breast cancer cells. It will be important to address
whether aggressive breast cancer cells form similar pat-
terned networks in culture and in vivo, as are seen in
melanoma. If tumor vasculogenesis can be demonstrated
in experimental models, does it occur concomitantly with
angiogenesis or as a remodeling of angiogenesis in
aggressive tumors? Is pre-existing vessel cooption
involved? Is tumor cell vasculogenesis an alternative
angiogenic switch in aggressive tumors? Regardless of
the terminology that is used to describe the expression
and mimicry of vascular-like genes by aggressive tumor
cells, this area of research merits further exploration, with
potential benefits for molecular diagnosis and therapeutic
intervention strategies. Carmeliet [51], in a review of the
mechanisms that underlie angiogenesis and arteriogene-
sis, speculated that the recent controversial findings of
mosaic tumor vessels and vasculogenic tumor cells (vas-
culogenic mimicry) “may have considerable conse-
quences for antiangiogenesis tumor therapy”.
Conclusion
There is a growing body of evidence suggesting that vas-
culogenic mimicry occurs in melanoma, and possibly other
cancers as well; however, the significance of this finding
remains under investigation. New evidence regarding the
possible existence of vasculogenic mimicry in aggressive
human breast cancer cells has been presented. We hope
that our paper will encourage other investigators to
examine breast tumors and other cancers for the putative
biological significance of the molecular expression of vas-
cular markers in aggressive cancers cells.
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Table 1
Summary of vascular marker expression
Human breast Thrombin Endothelin B
cancer cells receptor receptor TIE-2 CD31 Endoglin Angiopoietin-1 VEGF L32 GAPDH
HUVEC ++ ++* +++ ++ ++ ++ ++ ++ ++
MCF-7 ––––– – + + + + +
MB-231 ++ ++ + + – – +++ ++ ++
Comparison of qualitative expression assessment of vascular markers by human breast cancer cells MCF-7 (poorly aggressive), MDA-MB-231
(MB-231; highly aggressive) and HUVECs, as shown in the raw data from the ribonuclease protection assay and differential display analysis in
Figure 1. Equal loading of experimental samples was achieved by ribosomal protein L32 (L32) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) control lanes. *Data not shown.References
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